Sat, Dec 27, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

80 Capital opens Helium strategy to external investors after 23-month trading run

Monday, February 03, 2014
Opalesque Industry Update, for New Managers - Quantitative hedge fund manager 80 Capital LLP, run by former Deutsche Bank quantitative executive Philippe Azoulay, has opened its Helium strategy to external investors following a successful 23-month trading run and the acquisition of substantial seed capital.

The Helium strategy takes a unique approach to trading global managed futures. Developed by Azoulay within Deutsche Bank, it is being spun out as the first external investment of newly established 80 Capital LLP, which has received $50 million in seed capital investment from the bank.

“Receiving this level of institutional backing is unprecedented. It demonstrates the power of the Helium strategy,” said Azoulay.

Helium outperformed most of its managed futures peers in the 23 months from February 2012 with an average annualised outperformance of approximately 10% against major managed futures indices in a generally challenging period for managed futures. It had more positive months than its benchmark indices (64%) and a positive Sharpe ratio.

The strategy’s cumulative performance was 10.87%, its annualised performance 5.71%.

“By using a variety of techniques to catch statistical phenomenon on a medium- to long-term horizon and under a strict risk control structure, Helium is able to offer real alpha-generating power,” explained Azoulay.

Helium divides the trading universe into clusters of futures contracts, from which combinations of contracts are filtered and then systematically analysed to find trading signals. It thus generates alpha from correlation deformation as well as from price movement. The majority of quantitative funds build positions incrementally based on a signal strength type of criteria, such as the number of standard deviations above a threshold. However, this approach can lead to overweight positions with no statistical robustness that can quickly lose value. Helium, by contrast, uses cutting edge techniques that aim to eliminate the threat of exposure to a sudden fall.

“It’s about estimating how wrong we can be and then confronting that probability. That gives us a performance edge over the medium and long term,” Azoulay added.

80 Capital LLP is headquartered in London and authorised by the Financial Conduct Authority (FCA).

Press release
Bg

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its